Jerusalem, Israel – April 1, 2018
The first fruits of the successful collaboration between NovellusDX and Christiana Care Gene Editing Institute (GEI) resulted in the new article named “CRISPR-Directed In Vitro Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract”.
The article describes the novel method for creating point-mutations using CRISPR-Cas12a (Cpf1) enzyme. This new and exciting method was shown to be much more efficient and less error-prone than conventional PCR-based site-directed mutagenesis methods.
Currently, a second article is on the way, describing the specific method used by NovellusDX to create patient-derived mutations in-vitro.
Read the full article at: https://www.liebertpub.com/doi/10.1089/crispr.2018.0006
NovellusDx’s mission is to provide functional information about mutations and their responses to drugs so that oncologists can treat patients with precision therapies and bio-pharmaceutical companies can develop drugs more effectively. The NovellusDx approach is to monitor the functional effects of mutations and observe the effects of drugs, drug combinations and drug candidates on the activity level caused by the mutations. NovellusDx’s headquarters and research and development operations are based in Jerusalem, Israel.
To learn more about NovellusDx please visit www.novellus.bio